drugset / Trial / NCT00059917

Polyglutamate Camptothecin in Treating Patients With Advanced Cancer

NCT00059917 ↗

Treatment

Summary

RATIONALE: Drugs used in chemotherapy such as polyglutamate camptothecin may be able to deliver the drug directly to tumor cells while leaving normal cells undamaged. PURPOSE: Phase I trial to study the effectiveness of polyglutamate camptothecin in treating patients who have advanced cancer.

Timeline

Start
2003-01
Primary completion
—
Completion
2005-05

Publications

  • Results McNamara MV, Doroshow JH, Dupont J, et al.: Preliminary pharmacokinetics of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. [Abstract] J Clin Oncol 22 (Suppl 14): A-2073, 145s, 2004.
  • Results Springett GM, Takimoto C, McNamara M, et al.: Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. [Abstract] J Clin Oncol 22 (Suppl 14): A-3127, 226s, 2004.

Drugs

EvaluationDrugModalityDoseRoute
Subject polyglutamate camptothecin Unknown — Intravenous